Obama Far From Approval on Syria Vote

http://www.bloomberg.com/infographics/2013-09-06/obama-seeks-congressional-vote-on-syria-strike.html

Peramivir sales in Japan

Shionogi announced Peramivir sales targets for their fiscal year ending March 31, 2010.

http://www.shionogi.co.jp/ir_en/news/detail/e_100126.pdf

Based on conservative estimates of 700,000 doses at $34 per dose to $64 per dose, Shionogi expects revenue of between $23.8 million and $44.i million. With an assumed 20% royalty split, BioCryst Pharmaceuticals (BCRX) revenue from Shionogi sales in Japan over the next two months is between $4.76 million to $8.82 million. These revenue figures flow straight to the bottom line, and with 38.2 million outstanding shares, the earnings per share from Japanese revenue over the next two months is significant.

Sales figures do not take into account milestone payments due BCRX, and do not include the manufacturing mark-up from sales of Peramivir Active Pharmaceutical Ingredient (API) to Shionogi.

As noted, Peramivir is gaining traction worldwide, as regulatory approvals and emergency use authorization (EUA) have been secured in North America, Asia, Europe, the Middle East, and Latin America.

See sidebar for disclaimers.

Disclosure: long BCRX shares.

DSCO

One of my laggards had a big day last night, after their meeting with their FDA. I suppose I could exit with a small gain after averaging down, but after the trials and tribulations of the former incompetent CEO, I'm tempted to wait it out until FDA approval. Surfaxin will save many lives with Respiratory Distress Syndrome, so I will hang in there.

http://philadelphia.bizjournals.com/philadelphia/stories/2009/09/28/daily17.html?ana=yfcpc

There was a chance Discover Laboratories (symbol "DSCO") would be forced to shut its doors, but there was just too much technology for it to collapse. A partnership, and accompanying cash, should enable DSCO to reach the finish line.

Disclosure: I am long shares of DSCO.